Trial Profile

A phase II investigator initiated trial of RS5614 for treatment of Novel corona virus lung injury

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RS 5614 (Primary)
Indications Lung injury
Focus Therapeutic Use

Most Recent Events

22 Feb 2024 According to a Renascience media release, this trial was conducted at seven centers. The first subject was enrolled in October 2020, when the "Delta strain" was prevalent, and the trial was completed in March 2021, making it a fast and efficient trial (the clinical study report was completed in June 2021).
22 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com